AH-130 FN Cells

AH-130 FN is a variant of the AH-130 rat ascites tumor cell line, used extensively in studies related to coagulation, fibrinolysis, and metastasis. These cells were derived from rats and are typically maintained by serial intraperitoneal implantation in male Donryu rats. The AH-130 line itself is known for its high thromboplastic and fibrinolytic activities, which are linked to its role in promoting blood-borne metastasis, especially in the lungs. In contrast, the AH-130 FN variant has lower thromboplastic and fibrinolytic activity. This difference in enzymatic activity between AH-130 and AH-130 FN is crucial as it influences the formation of thrombi and the number of metastatic foci in the lungs following intravenous inoculation. Research has shown that after intravenous injection, AH-130 cells cause a significant reduction in platelet count and fibrinogen levels, indicative of increased thrombus formation. This effect is notably more pronounced than in AH-130 FN. Histological studies demonstrate that AH-130 forms more abundant metastatic foci in the lungs compared to AH-130 FN, both at 72 hours and 7 days post-inoculation. AH-130 is associated with the formation of thrombi composed of platelets and fibrin around embolized tumor cells, whereas AH-130 FN shows sparse thrombus formation. These findings suggest that AH-130’s higher thromboplastic activity plays a significant role in promoting metastasis through platelet aggregation and fibrin deposition around the tumor cells, a process less prominent in AH-130 FN.